Form 4: Eli Lilly Executive Eric Dozier Reports Stock Transactions

Executive Vice President of Human Resources and Diversity at Eli Lilly, Eric Dozier, reports the acquisition and disposal of company stock and restricted stock units.

Summary

• Eric Dozier, an Executive Vice President at Eli Lilly, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On November 1, 2024, Dozier acquired 1,534 shares of common stock through the vesting of restricted stock units.
• Also on November 1, 2024, he disposed of 681.403 shares of common stock to cover tax obligations at a price of $818.93 per share.
• Following these transactions, Dozier directly owns 8,042.597 shares of common stock and indirectly owns 291.66 shares through a 401(k) plan.
• He also holds 0 restricted stock units after the vesting.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and Eli Lilly's filing is consistent with these requirements.
• The transactions are typical for executives who receive stock-based compensation, such as restricted stock units, which vest over time.
• The sale of shares to cover tax obligations is also a common practice among executives who receive equity compensation.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate a change in the company's fundamentals.
• The transactions are part of the executive's compensation package and do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Executive Compensation, Eli Lilly, LLY, Insider Trading